Reaction

Immune Thrombocytopenic Purpura reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,832 reports · 55 co-occurring drugs

As of the last recalculation, Immune Thrombocytopenic Purpura appears in 2,832 FAERS reports alongside 55 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 179.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Alemtuzumab	406	179.9	183.8
Romiplostim	61	30.4	30.5
Eltrombopag Olamine	60	19.5	19.6
Bendamustine Hydrochloride	25	15.5	15.5
Fludarabine Phosphate	70	13.4	13.4
Dimenhydrinate	17	11.8	11.8
Guanfacine	11	10.3	10.3
Quinine	11	9.5	9.5
Tranexamic Acid	11	9.1	9.1
Raltegravir	20	9.0	9.0
Nivolumab	106	8.3	8.3
Basiliximab	13	8.2	8.2
Ado-Trastuzumab Emtansine	9	7.9	7.9
Melphalan	24	7.8	7.8
Thiotepa	10	7.7	7.7
Oxaliplatin	73	7.4	7.4
Cefepime	14	7.2	7.2
Bleomycin Sulfate	10	7.1	7.1
Melphalan Hydrochloride	24	7.1	7.1
Busulfan	14	6.6	6.6
Ipilimumab	38	6.5	6.5
Ifosfamide	19	6.5	6.5
Cefepime Hydrochloride	14	6.4	6.4
Temozolomide	18	6.3	6.3
Sodium Bicarbonate	19	6.0	6.0
Sodium Bicarbonate Injection,	19	6.0	6.0
Brinzolamide	7	5.9	5.9
Vancomycin Hydrochloride	52	5.9	5.9
Granisetron Hydrochloride	8	5.6	5.6
Granisetron	8	5.6	5.6
Vancomycin	42	5.4	5.4
Eplerenone	9	5.2	5.2
Rituximab	137	5.0	5.0
Fingolimod Hcl	56	4.8	4.8
Durvalumab	13	4.7	4.7
Fluorouracil Cream, 0.5%	46	4.5	4.5
Fluorouracil	46	4.4	4.4
Darunavir	9	4.4	4.4
Pitavastatin Calcium	6	4.3	4.3
Ledipasvir And Sofosbuvir	11	4.2	4.2
Pembrolizumab	58	4.1	4.1
Sofosbuvir	10	3.7	3.7
Ribavirin	31	3.6	3.6
Ibrutinib	38	3.5	3.5
Bevacizumab	56	3.4	3.4
Pemetrexed Disodium	17	3.3	3.3
Pemetrexed	9	3.1	3.1
Gemcitabine	16	3.0	3.0
Obinutuzumab	6	2.7	2.7
Gemcitabine Hydrochloride	19	2.6	2.6
Emtricitabine And Tenofovir Disoproxil Fumarate	15	2.4	2.4
Cetuximab	10	2.4	2.4
Venetoclax	18	2.2	2.2
Atezolizumab	11	2.1	2.1
Dimethyl Fumarate	25	1.5	1.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.